Orthos Europe has been acquired by Atrium Innovations
Holland Venture has sold Orthos Europe to Atrium Innovations.
Orthos Europe’s main brand is AOV under which high-quality food supplements such as multi-vitamins, minerals, probiotics, enzymes, fatty acids and antioxidants are developed and marketed. The company was founded over 20 years ago and has a very strong position in the Netherlands, where it is a leading player in its market segment.
Atrium Innovations is a developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. Atrium markets a portfolio of finished products through its sales and marketing network in more than 35 countries, primarily in North America and Europe.
Holland Venture is an independent private equity fund located in Amsterdam. Since 1981, Holland Venture has realized the growth potential of many of its investments and has proven to be a trustworthy partner.
Oaklins' team in the Netherlands advised the seller in this transaction.


Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more